GDC-9545 (Giredestrant) is a selective estrogen receptor degrader (SERD) being developed by Genentech as a potential treatment for ER+/HER- breast cancer. This talk will describe the development of a highly efficient and convergent commercial route of GDC-9545. The design and development of a green and sustainable API manufacturing process featuring a High Throughput Experimentation guided C–N coupling and diastereoselective crystallization driven Pictet–Spengler reaction.

Efficient manufacturing process for the selective estrogen receptor degrader GDC-9545 (Giredestrant)

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.